USP17L2

Summary

USP17L2 (ubiquitin specific peptidase 17 like family member 2, HGNC:34434) is a protein-coding gene on chromosome 8p23.1, encoding Ubiquitin carboxyl-terminal hydrolase 17 (Q6R6M4). Deubiquitinating enzyme that removes conjugated ubiquitin from specific proteins to regulate different cellular processes.

Enables cysteine-type deubiquitinase activity. Involved in several processes, including CAAX-box protein processing; protein deubiquitination; and regulation of defense response. Located in endoplasmic reticulum membrane and nucleus.

Source: NCBI Gene 377630 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 1 total
• Druggable target: yes
• MANE Select transcript: NM_201402

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:34434
Approved symbol	USP17L2
Name	ubiquitin specific peptidase 17 like family member 2
Location	8p23.1
Locus type	gene with protein product
Status	Approved
Aliases	DUB3
Ensembl gene	ENSG00000223443
Ensembl biotype	protein_coding
OMIM	610186
Entrez	377630

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000333796

RefSeq mRNA: 1 — MANE Select: NM_201402 NM_201402

CCDS: CCDS43713

Canonical transcript exons

ENST00000333796 — 1 exons

Exon	Start	End
ENSE00002199524	12136435	12138849

Expression profiles

Bgee: expression breadth broad, 42 present calls, max score 84.66.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0228 / max 5.2550, expressed in 12 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
91904	0.0228	12

Top tissues by expression

99 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.66	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	77.19	gold quality
corpus callosum	UBERON:0002336	75.04	gold quality
sural nerve	UBERON:0015488	62.93	gold quality
calcaneal tendon	UBERON:0003701	54.92	silver quality
primary visual cortex	UBERON:0002436	52.64	gold quality
stromal cell of endometrium	CL:0002255	51.68	silver quality
adrenal tissue	UBERON:0018303	50.46	silver quality
superior frontal gyrus	UBERON:0002661	48.97	gold quality
monocyte	CL:0000576	47.29	silver quality
leukocyte	CL:0000738	47.17	silver quality
colonic epithelium	UBERON:0000397	45.96	gold quality
ventricular zone	UBERON:0003053	43.73	gold quality
putamen	UBERON:0001874	43.54	gold quality
bone marrow cell	CL:0002092	42.82	gold quality
caudate nucleus	UBERON:0001873	42.81	gold quality
right frontal lobe	UBERON:0002810	42.04	gold quality
nucleus accumbens	UBERON:0001882	41.56	gold quality
tonsil	UBERON:0002372	41.52	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	41.51	gold quality
Brodmann (1909) area 9	UBERON:0013540	41.41	silver quality
skeletal muscle tissue	UBERON:0001134	40.31	gold quality
brain	UBERON:0000955	39.99	gold quality
temporal lobe	UBERON:0001871	39.78	gold quality
left ovary	UBERON:0002119	39.75	silver quality
amygdala	UBERON:0001876	39.47	gold quality
anterior cingulate cortex	UBERON:0009835	39.16	silver quality
cerebral cortex	UBERON:0000956	39.01	gold quality
Ammon’s horn	UBERON:0001954	38.54	silver quality
hypothalamus	UBERON:0001898	38.05	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.17

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 18)

• human DUB-3, like the murine DUB family members, is transiently induced in response to cytokines and can, when constitutively expressed, block growth factor-dependent proliferation. (PMID:14699124)
• Identifies DUB3 as being one of 30 genes with the most variable copy numbers in three human genomes. (PMID:19718026)
• As a major regulator of Cdc25A, Dub3 is an example of a transforming ubiquitin hydrolase that subverts a key component of the cell cycle machinery, promoting oncogenic transformation. (PMID:20228808)
• Recently, much progress has been made in understanding the physiological functions of cytokine-inducible DUBs such as DUB-1, DUB-2, and DUB-3/USP17, in regulation of cell proliferation and apoptosis in lymphocytes. [review] (PMID:23773437)
• Dub3 counteracts H2AX E3 ligases RNF8 and RNF168. Moreover, Dub3 and H2AX interact and Dub3 deubiquitinates H2AX in vitro. (PMID:24704006)
• These data indicate that the Dub3 might be a valuable biomarker for the prediction of ovarian cancer prognosis and Dub3 inhibition might be a potential strategy for ovarian cancer treatment. (PMID:25776484)
• In cigarette smoke extract-exposed airway epithelial cells and macrophages, HDAC2 is excessively ubiquitinated and degraded in the proteasome attributed to low expression of USP17. (PMID:26617781)
• We provide evidence that DUB3 proteins regulate YAP/TAZ activity by controlling the stability of the E3 ligase ITCH, the LATS kinases and the AMOT family proteins. As a novel Hippo pathway regulator, DUB3 has the potential to act a tumor suppressor by limiting YAP activity. (PMID:28061504)
• Dub3 is identified as a bona fide Snail1 deubiquitinase, which interacts with and stabilizes Snail1. (PMID:28198361)
• these data identify DUB3 and USP7 as factors that regulate DNA replication by controlling Geminin protein stability, and suggest that USP7 may be involved in Geminin dysregulation during breast cancer progression. (PMID:28288134)
• DUB3 promotes BET inhibitor resistance and cancer progression by deubiquitinating BRD4. (PMID:30057199)
• further analysis revealed 2 hemizygous deletions in the grandmother that segregate in several of her affected offspring. The first deletion was found in the UGT2B28 locus, spanning 7 informative sequence variants across at least 14 kb. The second deletion, located in USP17L2, spans 3 informative variants across at least 2 kb. On the whole, the findings of the presents study implicate 2 additional genes in the pathogenesis (PMID:30628680)
• our results revealed the essential role of the MGMT-DUB3-MCL1 axis in the chemoresistance of ovarian cancer and identified that a combined treatment with HDACis and PaTrin-2 is an effective method for overcoming chemoresistance in ovarian cancer. (PMID:30718431)
• DUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer. (PMID:30778200)
• DUB3 functions as a novel cyclin A regulator through maintaining cyclin A stability. (PMID:30935108)
• NXN suppresses metastasis of hepatocellular carcinoma by promoting degradation of Snail through binding to DUB3. (PMID:35927236)
• USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells. (PMID:36040642)
• Clinicopathological Significance of DUB3 Expression in Non-small Cell Lung Cancer and Relationship Between DUB3 Expression and LATS1 Expression. (PMID:37652526)

Cross-species orthologs

0 orthologs

Paralogs (71): USP2 (ENSG00000036672), USP28 (ENSG00000048028), USP36 (ENSG00000055483), USP13 (ENSG00000058056), USP33 (ENSG00000077254), USP40 (ENSG00000085982), USP48 (ENSG00000090686), USP14 (ENSG00000101557), USP11 (ENSG00000102226), USP10 (ENSG00000103194), USP31 (ENSG00000103404), USP42 (ENSG00000106346), USP5 (ENSG00000111667), USP4 (ENSG00000114316), USP9Y (ENSG00000114374), USP34 (ENSG00000115464), USP35 (ENSG00000118369), USP45 (ENSG00000123552), USP22 (ENSG00000124422), USP9X (ENSG00000124486), USP6 (ENSG00000129204), USP29 (ENSG00000131864), USP26 (ENSG00000134588), USP30 (ENSG00000135093), USP15 (ENSG00000135655), USP37 (ENSG00000135913), USP44 (ENSG00000136014), USP20 (ENSG00000136878), USP8 (ENSG00000138592), USP3 (ENSG00000140455), USP21 (ENSG00000143258), USP43 (ENSG00000154914), USP25 (ENSG00000155313), USP16 (ENSG00000156256), USP24 (ENSG00000162402), USP1 (ENSG00000162607), USP49 (ENSG00000164663), USP38 (ENSG00000170185), USP50 (ENSG00000170236), USP47 (ENSG00000170242)

Protein

Protein identifiers

Ubiquitin carboxyl-terminal hydrolase 17 — Q6R6M4 (reviewed: Q6R6M4)

Alternative names: Deubiquitinating enzyme 17-like protein 2, Deubiquitinating protein 3, Ubiquitin carboxyl-terminal hydrolase 17-like protein 2, Ubiquitin thioesterase 17-like protein 2, Ubiquitin-specific-processing protease 17-like protein 2

All UniProt accessions (1): Q6R6M4

UniProt curated annotations — full annotation on UniProt →

Function. Deubiquitinating enzyme that removes conjugated ubiquitin from specific proteins to regulate different cellular processes. Regulates cell proliferation by deubiquitinating and inhibiting RCE1 thereby controlling the small GTPases NRAS and HRAS localization and activation. In parallel, mediates deubiquitination of CDC25A, preventing CDC25A degradation by the proteasome during the G1/S and G2/M phases promoting cell-cycle progression. Also regulates cell proliferation and apoptosis through deubiquitination of SUDS3 a regulator of histone deacetylation. Through activation of the Rho family GTPases RAC1A, CDC42 and RHOA, regulates cell migration. Through the cleavage of ‘Lys-48’- and ‘Lys-63’-linked polyubiquitin chains of the cytoplasmic innate immune receptors RIGI and IFIH1 stimulates the cellular response to viral infection.

Subunit / interactions. Interacts with SUDS3; the interaction is direct.

Subcellular location. Nucleus. Endoplasmic reticulum.

Tissue specificity. Broadly expressed.

Induction. Up-regulated by IL4/interleukin-4, IL6/interleukin-6 and chemokines including CXCL8 and CXCL12 (at protein level). Up-regulated during the G1/S transition of the cell cycle.

Miscellaneous. Overexpressed in a subset of human breast cancers, overexpression leading to an abnormally high level of CDC25A, which arrests cells through replication stress or premature mitosis, the latter occurring when CDK1 is activated inappropriately.

Similarity. Belongs to the peptidase C19 family. USP17 subfamily.

RefSeq proteins (1): NP_958804* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001394	Peptidase_C19_UCH	Domain
IPR018200	USP_CS	Conserved_site
IPR028889	USP	Domain
IPR038765	Papain-like_cys_pep_sf	Homologous_superfamily
IPR050164	Peptidase_C19	Family

Pfam: PF00443

UniProt features (26 total): sequence conflict 13, compositionally biased region 4, region of interest 3, active site 2, chain 1, domain 1, sequence variant 1, mutagenesis site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6R6M4-F1	67.79	0.47

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 334 (proton acceptor); 89 (nucleophile)

Mutagenesis-validated functional residues (1):

Position	Phenotype
89	abolishes both enzymatic activity and effects on cell proliferation.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-5689880	Ub-specific processing proteases
R-HSA-9648002	RAS processing

MSigDB gene sets: 138 (showing top): GOBP_NEGATIVE_REGULATION_OF_PROTEOLYSIS, GOBP_REGULATION_OF_DEFENSE_RESPONSE_TO_VIRUS, GOBP_NEGATIVE_REGULATION_OF_HYDROLASE_ACTIVITY, GOBP_CELL_CYCLE_PHASE_TRANSITION, GOBP_PROTEIN_TARGETING, GOBP_REGULATION_OF_GTPASE_ACTIVITY, GOBP_REGULATION_OF_RUFFLE_ASSEMBLY, GOBP_REGULATION_OF_PROTEIN_TARGETING_TO_MEMBRANE, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_REMOVAL, GOBP_REGULATION_OF_CELL_CYCLE_G2_M_PHASE_TRANSITION, GOBP_POSITIVE_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS, GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY, GOBP_REGULATION_OF_HYDROLASE_ACTIVITY, GOBP_REGULATION_OF_IMMUNE_RESPONSE

GO Biological Process (20): MAPK cascade (GO:0000165), apoptotic process (GO:0006915), negative regulation of protein processing (GO:0010955), protein deubiquitination (GO:0016579), regulation of cell migration (GO:0030334), regulation of protein stability (GO:0031647), negative regulation of GTPase activity (GO:0034260), regulation of cell population proliferation (GO:0042127), regulation of apoptotic process (GO:0042981), positive regulation of GTPase activity (GO:0043547), regulation of defense response to virus by host (GO:0050691), protein K63-linked deubiquitination (GO:0070536), protein K48-linked deubiquitination (GO:0071108), CAAX-box protein processing (GO:0071586), negative regulation of protein targeting to membrane (GO:0090315), regulation of G2/MI transition of meiotic cell cycle (GO:0110030), regulation of ruffle assembly (GO:1900027), positive regulation of MDA-5 signaling pathway (GO:1900245), positive regulation of RIG-I signaling pathway (GO:1900246), proteolysis (GO:0006508)

GO Molecular Function (5): cysteine-type deubiquitinase activity (GO:0004843), protein binding (GO:0005515), peptidase activity (GO:0008233), cysteine-type peptidase activity (GO:0008234), hydrolase activity (GO:0016787)

GO Cellular Component (4): nucleus (GO:0005634), endoplasmic reticulum membrane (GO:0005789), cytosol (GO:0005829), endoplasmic reticulum (GO:0005783)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Deubiquitination	1
RAF/MAP kinase cascade	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein processing	2
GTPase activity	2
regulation of GTPase activity	2
protein deubiquitination	2
positive regulation of pattern recognition receptor signaling pathway	2
positive regulation of intracellular signal transduction	2
intracellular membrane-bounded organelle	2
cytoplasm	2
intracellular signaling cassette	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
negative regulation of proteolysis	1
regulation of protein processing	1
negative regulation of protein maturation	1
cysteine-type deubiquitinase activity	1
protein modification by small protein removal	1
cell migration	1
regulation of cell motility	1
regulation of biological quality	1
negative regulation of biological process	1
negative regulation of hydrolase activity	1
cell population proliferation	1
regulation of cellular process	1
apoptotic process	1
regulation of programmed cell death	1
positive regulation of hydrolase activity	1
regulation of defense response to virus	1
CAAX-box protein maturation	1
protein targeting to membrane	1
negative regulation of cellular process	1
regulation of protein targeting to membrane	1
negative regulation of establishment of protein localization	1
G2/MI transition of meiotic cell cycle	1
regulation of meiotic cell cycle phase transition	1
regulation of cell cycle G2/M phase transition	1
ruffle assembly	1
regulation of plasma membrane bounded cell projection assembly	1
positive regulation of immune effector process	1
MDA-5 signaling pathway	1

Protein interactions and networks

STRING

528 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
USP17L2	ZUP1	Q96AP4	912
USP17L2	SNAI1	O95863	623
USP17L2	USP13	Q92995	604
USP17L2	USP37	Q86T82	592
USP17L2	JOSD1	Q15040	591
USP17L2	RCE1	Q9Y256	560
USP17L2	FBXL14	Q8N1E6	546
USP17L2	USP28	Q96RU2	545
USP17L2	OTUD5	Q96G74	533
USP17L2	CDK4	P11802	533
USP17L2	JOSD2	Q8TAC2	528
USP17L2	OTUB1	Q96FW1	521
USP17L2	AMOT	Q4VCS5	520
USP17L2	USP26	Q9BXU7	519
USP17L2	USP25	Q9UHP3	515

IntAct

3 interactions, top by confidence:

A	B	Type	Score
USP17L24	USP17L7	psi-mi:“MI:0914”(association)	0.350
USP17L2	USP17L7	psi-mi:“MI:0914”(association)	0.350

BioGRID (130): LGMN (Biochemical Activity), USP17L2 (Co-fractionation), USP17L2 (Affinity Capture-Western), USP17L2 (Affinity Capture-Western), SUDS3 (Reconstituted Complex), SUDS3 (Affinity Capture-Western), SUDS3 (Affinity Capture-MS), USP17L2 (Affinity Capture-Western), HDAC2 (Affinity Capture-Western), USP17L2 (Affinity Capture-Western), IL33 (Affinity Capture-Western), USP17L2 (Affinity Capture-Western), SNAI1 (Affinity Capture-Western), SNAI1 (Reconstituted Complex), USP17L2 (Reconstituted Complex)

ESM2 similar proteins: A2A5N8, A6NCW0, A6NCW7, A8MUK1, B1AQJ2, B2RQC2, C9J2P7, C9JJH3, C9JLJ4, C9JPN9, C9JVI0, D3ZWK4, D6R901, D6R9N7, D6RA61, D6RBM5, D6RBQ6, D6RCP7, D6RJB6, E9Q9U0, G5E8G2, G5E8I7, O94966, P0C7H9, P0C7I0, P35125, P51784, Q0E2F9, Q0WX57, Q2TAC6, Q3UJD6, Q4KLL9, Q5R7G8, Q5TKR9, Q61068, Q66HE5, Q6J1Y9, Q6PFD6, Q6QN14, Q6R6M4

Diamond homologs: A0A0R4IB93, A0JM59, A5PMR2, A5PN09, A6NNY8, A6QNM7, A7Z056, B1AY13, B1WBD7, D2HBJ8, D6RBM5, E1C213, E7F6T8, E9Q9U0, F6Z5C0, F8VPU6, F8VPZ3, M9PD06, O00507, O22207, O60079, O74442, O94269, O94966, O96612, P0C7I0, P0C8Z3, P0CAQ1, P35125, P39538, P40453, P51784, P53874, P55824, P70398, Q01988, Q09738, Q0V9G5, Q28CN3, Q2HJE4

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
USP17L2	“down-regulates quantity by destabilization”	LGMN	deubiquitination
USP17L2	“up-regulates quantity by stabilization”	BHLHE40	deubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

1 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

46 predictions. Top by Δscore:

Variant	Effect	Δscore
8:12137469:T:TA	donor_gain	0.3800
8:12138645:T:TG	acceptor_gain	0.3700
8:12137984:C:G	acceptor_gain	0.3500
8:12137483:TTCC:T	donor_gain	0.3000
8:12137543:T:A	donor_gain	0.3000
8:12137386:GGGTA:G	donor_loss	0.2900
8:12137387:GGTA:G	donor_loss	0.2900
8:12137388:GTAC:G	donor_loss	0.2900
8:12137389:TA:T	donor_loss	0.2900
8:12137390:A:C	donor_loss	0.2900
8:12137391:C:T	donor_loss	0.2900
8:12137392:CTTCG:C	donor_loss	0.2800
8:12137643:A:C	acceptor_gain	0.2800
8:12138731:ACCTC:A	donor_gain	0.2800
8:12138732:CCTCC:C	donor_gain	0.2800
8:12137385:AGGGT:A	donor_loss	0.2700
8:12137639:C:CC	acceptor_gain	0.2700
8:12137375:G:C	donor_gain	0.2600
8:12137643:A:AC	acceptor_gain	0.2600
8:12138725:CCACT:C	donor_loss	0.2600
8:12138726:CACTC:C	donor_loss	0.2600
8:12138727:ACTCA:A	donor_loss	0.2600
8:12138728:CT:C	donor_loss	0.2600
8:12138729:T:TA	donor_loss	0.2600
8:12138730:CACCT:C	donor_loss	0.2600
8:12138731:AC:A	donor_loss	0.2600
8:12138732:C:T	donor_loss	0.2600
8:12138732:CCT:C	donor_gain	0.2600
8:12137634:CTCTT:C	acceptor_gain	0.2500
8:12138624:T:TG	acceptor_gain	0.2400

AlphaMissense

3495 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:12137973:G:T	A263D	0.988
8:12137966:C:A	K265N	0.987
8:12137966:C:G	K265N	0.987
8:12138142:A:G	C207R	0.980
8:12137912:G:C	F283L	0.979
8:12137912:G:T	F283L	0.979
8:12137914:A:G	F283L	0.979
8:12138154:A:G	S203P	0.977
8:12138024:A:G	L246P	0.970
8:12138147:A:G	I205T	0.969
8:12138147:A:C	I205S	0.967
8:12138141:C:G	C207S	0.965
8:12138142:A:T	C207S	0.965
8:12137968:T:C	K265E	0.961
8:12138000:C:T	C254Y	0.961
8:12138024:A:T	L246H	0.961
8:12138121:A:G	S214P	0.961
8:12138140:A:C	C207W	0.961
8:12138133:A:G	C210R	0.960
8:12138001:A:G	C254R	0.958
8:12138131:G:C	C210W	0.958
8:12138132:C:G	C210S	0.958
8:12138133:A:T	C210S	0.958
8:12138132:C:T	C210Y	0.957
8:12138150:T:G	Q204P	0.955
8:12138160:A:G	W201R	0.955
8:12138160:A:T	W201R	0.955
8:12138000:C:G	C254S	0.954
8:12138001:A:T	C254S	0.954
8:12137974:C:G	A263P	0.953

dbSNP variants (sampled 300 via entrez): RS1008742680 (8:12140222 C>G,T), RS10090565 (8:12140019 G>A), RS10090570 (8:12140021 G>A), RS1012872703 (8:12139518 G>A), RS1017747908 (8:12136364 A>T), RS1022360289 (8:12138011 A>G), RS1030536033 (8:12136194 G>A), RS1031036734 (8:12138781 C>G), RS1031066170 (8:12140187 T>C), RS1035318720 (8:12138552 A>C,G), RS1038820269 (8:12137439 TGGG>T,TGG,TGGGG), RS1039095503 (8:12138452 G>C,T), RS1042709438 (8:12135947 T>C), RS1042853860 (8:12137345 C>G,T), RS1043714759 (8:12139659 A>G)

Disease associations

OMIM: gene MIM:610186 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3739248 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

12 total (human), top 12 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression	1
butyraldehyde	increases expression	1
abrine	increases expression	1
(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II)	increases expression	1
Acetaminophen	increases expression	1
Air Pollutants	increases expression	1
Benzo(a)pyrene	decreases methylation	1
Cadmium	decreases expression	1
Rifampin	decreases expression	1
Thiram	increases expression	1
Valproic Acid	increases methylation	1
Lactic Acid	decreases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3744223	Binding	Inhibition of USP17 in human HEK293T cells using fluorogenic substrate ub-rhodamine110 preincubated for 30 mins followed by substrate addition measured every 4 mins for 1 hr by microplate reader analysis	Development of a potent and selective cell penetrant Legumain inhibitor. — Bioorg Med Chem Lett

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.